The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neuraminidase Inhibitor Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2028
Synopsis
The Neuraminidase Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neuraminidase Inhibitor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital Pharmacies accounting for % of the Neuraminidase Inhibitor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Zanamivir segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neuraminidase Inhibitor include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, BioCryst, and Daiichi Sankyo, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neuraminidase Inhibitor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Zanamivir
Oseltamivir
Peramivir
Laninamivir
Market segment by Application can be divided into
Hospital Pharmacies
Drug Stores
Retail Stores
Others
The key market players for global Neuraminidase Inhibitor market are listed below:
GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
BioCryst
Daiichi Sankyo
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuraminidase Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuraminidase Inhibitor, with price, sales, revenue and global market share of Neuraminidase Inhibitor from 2019 to 2022.
Chapter 3, the Neuraminidase Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuraminidase Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neuraminidase Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuraminidase Inhibitor.
Chapter 13, 14, and 15, to describe Neuraminidase Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Geographical Area
Global
The Neuraminidase Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neuraminidase Inhibitor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital Pharmacies accounting for % of the Neuraminidase Inhibitor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Zanamivir segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neuraminidase Inhibitor include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, BioCryst, and Daiichi Sankyo, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neuraminidase Inhibitor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Zanamivir
Oseltamivir
Peramivir
Laninamivir
Market segment by Application can be divided into
Hospital Pharmacies
Drug Stores
Retail Stores
Others
The key market players for global Neuraminidase Inhibitor market are listed below:
GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
BioCryst
Daiichi Sankyo
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuraminidase Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuraminidase Inhibitor, with price, sales, revenue and global market share of Neuraminidase Inhibitor from 2019 to 2022.
Chapter 3, the Neuraminidase Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuraminidase Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neuraminidase Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuraminidase Inhibitor.
Chapter 13, 14, and 15, to describe Neuraminidase Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Neuraminidase Inhibitor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuraminidase Inhibitor Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Zanamivir
1.2.3 Oseltamivir
1.2.4 Peramivir
1.2.5 Laninamivir
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuraminidase Inhibitor Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacies
1.3.3 Drug Stores
1.3.4 Retail Stores
1.3.5 Others
1.4 Global Neuraminidase Inhibitor Market Size & Forecast
1.4.1 Global Neuraminidase Inhibitor Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Neuraminidase Inhibitor Sales in Volume (2017-2028)
1.4.3 Global Neuraminidase Inhibitor Price (2017-2028)
1.5 Global Neuraminidase Inhibitor Production Capacity Analysis
1.5.1 Global Neuraminidase Inhibitor Total Production Capacity (2017-2028)
1.5.2 Global Neuraminidase Inhibitor Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuraminidase Inhibitor Market Drivers
1.6.2 Neuraminidase Inhibitor Market Restraints
1.6.3 Neuraminidase Inhibitor Trends Analysis
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 GlaxoSmithKline Details
2.1.2 GlaxoSmithKline Major Business
2.1.3 GlaxoSmithKline Neuraminidase Inhibitor Product and Services
2.1.4 GlaxoSmithKline Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Gilead Sciences
2.2.1 Gilead Sciences Details
2.2.2 Gilead Sciences Major Business
2.2.3 Gilead Sciences Neuraminidase Inhibitor Product and Services
2.2.4 Gilead Sciences Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 F. Hoffman-La Roche
2.3.1 F. Hoffman-La Roche Details
2.3.2 F. Hoffman-La Roche Major Business
2.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Product and Services
2.3.4 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 BioCryst
2.4.1 BioCryst Details
2.4.2 BioCryst Major Business
2.4.3 BioCryst Neuraminidase Inhibitor Product and Services
2.4.4 BioCryst Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Daiichi Sankyo
2.5.1 Daiichi Sankyo Details
2.5.2 Daiichi Sankyo Major Business
2.5.3 Daiichi Sankyo Neuraminidase Inhibitor Product and Services
2.5.4 Daiichi Sankyo Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Neuraminidase Inhibitor Breakdown Data by Manufacturer
3.1 Global Neuraminidase Inhibitor Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Neuraminidase Inhibitor Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Neuraminidase Inhibitor
3.4 Market Concentration Rate
3.4.1 Top 3 Neuraminidase Inhibitor Manufacturer Market Share in 2021
3.4.2 Top 6 Neuraminidase Inhibitor Manufacturer Market Share in 2021
3.5 Global Neuraminidase Inhibitor Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Neuraminidase Inhibitor Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Neuraminidase Inhibitor Market Size by Region
4.1.1 Global Neuraminidase Inhibitor Sales in Volume by Region (2017-2028)
4.1.2 Global Neuraminidase Inhibitor Revenue by Region (2017-2028)
4.2 North America Neuraminidase Inhibitor Revenue (2017-2028)
4.3 Europe Neuraminidase Inhibitor Revenue (2017-2028)
4.4 Asia-Pacific Neuraminidase Inhibitor Revenue (2017-2028)
4.5 South America Neuraminidase Inhibitor Revenue (2017-2028)
4.6 Middle East and Africa Neuraminidase Inhibitor Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Neuraminidase Inhibitor Sales in Volume by Type (2017-2028)
5.2 Global Neuraminidase Inhibitor Revenue by Type (2017-2028)
5.3 Global Neuraminidase Inhibitor Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Neuraminidase Inhibitor Sales in Volume by Application (2017-2028)
6.2 Global Neuraminidase Inhibitor Revenue by Application (2017-2028)
6.3 Global Neuraminidase Inhibitor Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Neuraminidase Inhibitor Sales by Type (2017-2028)
7.2 North America Neuraminidase Inhibitor Sales by Application (2017-2028)
7.3 North America Neuraminidase Inhibitor Market Size by Country
7.3.1 North America Neuraminidase Inhibitor Sales in Volume by Country (2017-2028)
7.3.2 North America Neuraminidase Inhibitor Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Neuraminidase Inhibitor Sales by Type (2017-2028)
8.2 Europe Neuraminidase Inhibitor Sales by Application (2017-2028)
8.3 Europe Neuraminidase Inhibitor Market Size by Country
8.3.1 Europe Neuraminidase Inhibitor Sales in Volume by Country (2017-2028)
8.3.2 Europe Neuraminidase Inhibitor Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Neuraminidase Inhibitor Sales by Type (2017-2028)
9.2 Asia-Pacific Neuraminidase Inhibitor Sales by Application (2017-2028)
9.3 Asia-Pacific Neuraminidase Inhibitor Market Size by Region
9.3.1 Asia-Pacific Neuraminidase Inhibitor Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Neuraminidase Inhibitor Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Neuraminidase Inhibitor Sales by Type (2017-2028)
10.2 South America Neuraminidase Inhibitor Sales by Application (2017-2028)
10.3 South America Neuraminidase Inhibitor Market Size by Country
10.3.1 South America Neuraminidase Inhibitor Sales in Volume by Country (2017-2028)
10.3.2 South America Neuraminidase Inhibitor Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Neuraminidase Inhibitor Sales by Type (2017-2028)
11.2 Middle East & Africa Neuraminidase Inhibitor Sales by Application (2017-2028)
11.3 Middle East & Africa Neuraminidase Inhibitor Market Size by Country
11.3.1 Middle East & Africa Neuraminidase Inhibitor Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Neuraminidase Inhibitor Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Neuraminidase Inhibitor and Key Manufacturers
12.2 Manufacturing Costs Percentage of Neuraminidase Inhibitor
12.3 Neuraminidase Inhibitor Production Process
12.4 Neuraminidase Inhibitor Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Neuraminidase Inhibitor Typical Distributors
13.3 Neuraminidase Inhibitor Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of TablesList of Tables
Table 1. Global Neuraminidase Inhibitor Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Neuraminidase Inhibitor Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 4. GlaxoSmithKline Major Business
Table 5. GlaxoSmithKline Neuraminidase Inhibitor Product and Services
Table 6. GlaxoSmithKline Neuraminidase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 8. Gilead Sciences Major Business
Table 9. Gilead Sciences Neuraminidase Inhibitor Product and Services
Table 10. Gilead Sciences Neuraminidase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. F. Hoffman-La Roche Basic Information, Manufacturing Base and Competitors
Table 12. F. Hoffman-La Roche Major Business
Table 13. F. Hoffman-La Roche Neuraminidase Inhibitor Product and Services
Table 14. F. Hoffman-La Roche Neuraminidase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. BioCryst Basic Information, Manufacturing Base and Competitors
Table 16. BioCryst Major Business
Table 17. BioCryst Neuraminidase Inhibitor Product and Services
Table 18. BioCryst Neuraminidase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 20. Daiichi Sankyo Major Business
Table 21. Daiichi Sankyo Neuraminidase Inhibitor Product and Services
Table 22. Daiichi Sankyo Neuraminidase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Global Neuraminidase Inhibitor Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 24. Global Neuraminidase Inhibitor Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 25. Market Position of Manufacturers in Neuraminidase Inhibitor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 26. Global Neuraminidase Inhibitor Production Capacity by Company, (K Units): 2020 VS 2021
Table 27. Head Office and Neuraminidase Inhibitor Production Site of Key Manufacturer
Table 28. Neuraminidase Inhibitor New Entrant and Capacity Expansion Plans
Table 29. Neuraminidase Inhibitor Mergers & Acquisitions in the Past Five Years
Table 30. Global Neuraminidase Inhibitor Sales by Region (2017-2022) & (K Units)
Table 31. Global Neuraminidase Inhibitor Sales by Region (2023-2028) & (K Units)
Table 32. Global Neuraminidase Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 33. Global Neuraminidase Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 34. Global Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 35. Global Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 36. Global Neuraminidase Inhibitor Revenue by Type (2017-2022) & (USD Million)
Table 37. Global Neuraminidase Inhibitor Revenue by Type (2023-2028) & (USD Million)
Table 38. Global Neuraminidase Inhibitor Price by Type (2017-2022) & (US$/Unit)
Table 39. Global Neuraminidase Inhibitor Price by Type (2023-2028) & (US$/Unit)
Table 40. Global Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 41. Global Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 42. Global Neuraminidase Inhibitor Revenue by Application (2017-2022) & (USD Million)
Table 43. Global Neuraminidase Inhibitor Revenue by Application (2023-2028) & (USD Million)
Table 44. Global Neuraminidase Inhibitor Price by Application (2017-2022) & (US$/Unit)
Table 45. Global Neuraminidase Inhibitor Price by Application (2023-2028) & (US$/Unit)
Table 46. North America Neuraminidase Inhibitor Sales by Country (2017-2022) & (K Units)
Table 47. North America Neuraminidase Inhibitor Sales by Country (2023-2028) & (K Units)
Table 48. North America Neuraminidase Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 49. North America Neuraminidase Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 50. North America Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 51. North America Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 52. North America Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 53. North America Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 54. Europe Neuraminidase Inhibitor Sales by Country (2017-2022) & (K Units)
Table 55. Europe Neuraminidase Inhibitor Sales by Country (2023-2028) & (K Units)
Table 56. Europe Neuraminidase Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 57. Europe Neuraminidase Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 58. Europe Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 59. Europe Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 60. Europe Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 61. Europe Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 62. Asia-Pacific Neuraminidase Inhibitor Sales by Region (2017-2022) & (K Units)
Table 63. Asia-Pacific Neuraminidase Inhibitor Sales by Region (2023-2028) & (K Units)
Table 64. Asia-Pacific Neuraminidase Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 65. Asia-Pacific Neuraminidase Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 66. Asia-Pacific Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 67. Asia-Pacific Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 68. Asia-Pacific Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 69. Asia-Pacific Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 70. South America Neuraminidase Inhibitor Sales by Country (2017-2022) & (K Units)
Table 71. South America Neuraminidase Inhibitor Sales by Country (2023-2028) & (K Units)
Table 72. South America Neuraminidase Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 73. South America Neuraminidase Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 74. South America Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 75. South America Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 76. South America Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 77. South America Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 78. Middle East & Africa Neuraminidase Inhibitor Sales by Region (2017-2022) & (K Units)
Table 79. Middle East & Africa Neuraminidase Inhibitor Sales by Region (2023-2028) & (K Units)
Table 80. Middle East & Africa Neuraminidase Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 81. Middle East & Africa Neuraminidase Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 82. Middle East & Africa Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 83. Middle East & Africa Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 84. Middle East & Africa Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 85. Middle East & Africa Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 86. Neuraminidase Inhibitor Raw Material
Table 87. Key Manufacturers of Neuraminidase Inhibitor Raw Materials
Table 88. Direct Channel Pros & Cons
Table 89. Indirect Channel Pros & Cons
Table 90. Neuraminidase Inhibitor Typical Distributors
Table 91. Neuraminidase Inhibitor Typical Customers
List of Figures
Figure 1. Neuraminidase Inhibitor Picture
Figure 2. Global Neuraminidase Inhibitor Revenue Market Share by Type in 2021
Figure 3. Zanamivir
Figure 4. Oseltamivir
Figure 5. Peramivir
Figure 6. Laninamivir
Figure 7. Global Neuraminidase Inhibitor Revenue Market Share by Application in 2021
Figure 8. Hospital Pharmacies
Figure 9. Drug Stores
Figure 10. Retail Stores
Figure 11. Others
Figure 12. Global Neuraminidase Inhibitor Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 13. Global Neuraminidase Inhibitor Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Neuraminidase Inhibitor Sales (2017-2028) & (K Units)
Figure 15. Global Neuraminidase Inhibitor Price (2017-2028) & (US$/Unit)
Figure 16. Global Neuraminidase Inhibitor Production Capacity (2017-2028) & (K Units)
Figure 17. Global Neuraminidase Inhibitor Production Capacity by Geographic Region: 2022 VS 2028
Figure 18. Neuraminidase Inhibitor Market Drivers
Figure 19. Neuraminidase Inhibitor Market Restraints
Figure 20. Neuraminidase Inhibitor Market Trends
Figure 21. Global Neuraminidase Inhibitor Sales Market Share by Manufacturer in 2021
Figure 22. Global Neuraminidase Inhibitor Revenue Market Share by Manufacturer in 2021
Figure 23. Neuraminidase Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 24. Top 3 Neuraminidase Inhibitor Manufacturer (Revenue) Market Share in 2021
Figure 25. Top 6 Neuraminidase Inhibitor Manufacturer (Revenue) Market Share in 2021
Figure 26. Global Neuraminidase Inhibitor Sales Market Share by Region (2017-2028)
Figure 27. Global Neuraminidase Inhibitor Revenue Market Share by Region (2017-2028)
Figure 28. North America Neuraminidase Inhibitor Revenue (2017-2028) & (USD Million)
Figure 29. Europe Neuraminidase Inhibitor Revenue (2017-2028) & (USD Million)
Figure 30. Asia-Pacific Neuraminidase Inhibitor Revenue (2017-2028) & (USD Million)
Figure 31. South America Neuraminidase Inhibitor Revenue (2017-2028) & (USD Million)
Figure 32. Middle East & Africa Neuraminidase Inhibitor Revenue (2017-2028) & (USD Million)
Figure 33. Global Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
Figure 34. Global Neuraminidase Inhibitor Revenue Market Share by Type (2017-2028)
Figure 35. Global Neuraminidase Inhibitor Price by Type (2017-2028) & (US$/Unit)
Figure 36. Global Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
Figure 37. Global Neuraminidase Inhibitor Revenue Market Share by Application (2017-2028)
Figure 38. Global Neuraminidase Inhibitor Price by Application (2017-2028) & (US$/Unit)
Figure 39. North America Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
Figure 40. North America Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
Figure 41. North America Neuraminidase Inhibitor Sales Market Share by Country (2017-2028)
Figure 42. North America Neuraminidase Inhibitor Revenue Market Share by Country (2017-2028)
Figure 43. United States Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Canada Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Mexico Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Europe Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
Figure 47. Europe Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
Figure 48. Europe Neuraminidase Inhibitor Sales Market Share by Country (2017-2028)
Figure 49. Europe Neuraminidase Inhibitor Revenue Market Share by Country (2017-2028)
Figure 50. Germany Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific Neuraminidase Inhibitor Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific Neuraminidase Inhibitor Sales Market Share by Region (2017-2028)
Figure 58. Asia-Pacific Neuraminidase Inhibitor Revenue Market Share by Region (2017-2028)
Figure 59. China Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Korea Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
Figure 66. South America Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
Figure 67. South America Neuraminidase Inhibitor Sales Market Share by Country (2017-2028)
Figure 68. South America Neuraminidase Inhibitor Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East & Africa Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
Figure 72. Middle East & Africa Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
Figure 73. Middle East & Africa Neuraminidase Inhibitor Sales Market Share by Region (2017-2028)
Figure 74. Middle East & Africa Neuraminidase Inhibitor Revenue Market Share by Region (2017-2028)
Figure 75. Turkey Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Egypt Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Saudi Arabia Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. South Africa Neuraminidase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Manufacturing Cost Structure Analysis of Neuraminidase Inhibitor in 2021
Figure 80. Manufacturing Process Analysis of Neuraminidase Inhibitor
Figure 81. Neuraminidase Inhibitor Industrial Chain
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
Figure 83. Methodology
Figure 84. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
